The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Census Conference

Canadian Journal of Anesthesia

Volumn 54, Issue 7, 2007, Pages 573-582

  Karkouti, Keyvan ^a   Beattie, W Scott ^b   Crowther, Mark A ^b   Callum, Jeannie L ^b   Chun, Rosaleen ^b   Fremes, Stephen E ^b   Lemieux, Jérôme ^b   McAlister, Vivian C ^b   Muirhead, Brian D ^b   Murkin, John M ^b   Nathan, Howard J ^b   Wong, Bill I ^b   Yau, Terrence M ^b   Yeo, Erik L ^b   Hall, Richard I ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; ARGIPRESSIN[1 DEAMINO]; PLACEBO; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ANTICOAGULANT THERAPY; BLOOD TRANSFUSION; CANADA; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART SURGERY; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; MEDICAL LITERATURE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL PATIENT; SURGICAL TECHNIQUE; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 34447649219     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022322     Document Type: Review

References (52)

1. Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995; 59: 664-7.
2. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-46.
3. Crabtree TD, Codd JE, Fraser VJ, Bailey MS, Olsen MA, Damiano RJ Jr. Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center. Semin Thorac Cardiovasc Surg 2004; 16: 53-61.
4. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62.
5. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327-38.
6. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105: 198-208.
7. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
8. Martinowitz U, Michaelson M; The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-8.
9. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.
10. Enomoto TM, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin 2005; 21: 611-32.
11. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn D. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006; 10: R120.
12. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006; 129: 174-81.
13. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.
14. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006; 17: 389-95.
15. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005; 94: 586-91.
16. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5.
17. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11: 895-900.
18. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102: 269-75.
19. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191: 245-9.
20. Lodge JP, Jonas S, Jones RM, et al; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-9.
21. Ballen J, Raabe M, Muirhead B. Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? Can J Anesth 2006; 53: 353-6.
22. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000; 26: 413-9.
23. Karkouti K, O'Farrell R, Yau TM, Beattie WS, Reducing Bleeding in Cardiac Surgery Research Group. Prediction of massive blood transfusion in cardiac surgery. Can J Anesth 2006; 53: 781-94.
24. Boffard KD, Riou B, Warren B, et al; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15.
25. Bosch J, Thabut D, Bendtsen F, et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30.
26. Pihusch M, Bacigalupo A, Szer J, et al; F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-44.
27. McCall P, Story DA, Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anesth 2006; 53: 926-33.
28. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/ NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang 2006; 90: 45-52.
29. Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Ann Thorac Surg 2006; 82: 1779-83.
30. Brandsborg S, Sorensen B, Poulsen LH, et al. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Blood Coagul Fibrinolysis 2006; 17: 241-9.
31. Walsham J, Fraser JF, Mullany D, et al. The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. Anaesth Intensive Care 2006; 34: 13-20.
32. Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 2006; 81: 875-9.
33. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005; 28: 254-8.
34. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 2005; 80: 66-71.
35. Halkos ME, Levy JH, Chen E, et al. Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg 2005; 79: 1303-6.
36. Aggarwal A, Malkovska V, Catlett JP, Alcom K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2004; 2: 9.
37. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul Fibrinolysis 2004; 15(suppl I): S31-2.
38. Eikelboom JW, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003; 14: 713-7.
39. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2004; 30: 682-5.
40. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(suppl 1):S121-7.
41. Karkouti K, Yau TM, Riazi S, et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anesth 2006; 53: 802-9.
42. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102: 1320-6.
43. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery - a retrospective analysis of safety and efficacy. Crit Care Med 2005; 33: 2241-6.
44. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
45. Clark AD, Gordon WC, Walker ID, Tait RC. 'Lastditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86: 120-4.
46. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(1 Suppl 1): 101-8.
47. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
48. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46: 919-33.
49. Mayer SA, Brun NC, Begtrup K, et al.; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-85.
50. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41(1 Suppl 1): 35-9.
51. Karkouti K, Yau TM, van Rensburg A, et al. The effects of a treatment protocol for cardiac surgical patients with excessive blood loss on clinical outcomes. Vox Sang 2006; 91: 148-56.
52. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.